论文部分内容阅读
目的探讨重组人血管内皮抑素联合放疗治疗非小细胞肺癌的临床效果。方法回顾性分析2010年2月间至2013年2月110例非小细胞肺癌患者资料,分为观察组和对照组(每组55例)。对照组患者采用放疗治疗,观察组患者加用重组人血管内皮抑素,比较两组患者的临床效果。结果观察组患者CR、PR、SD、PD的百分比分别为3.6%、47.3%、14.5%和34.6%,客观有效率(RR)为50.9%,疾病控制率(DCR)为65.5%。对照组患者CR、PR、SD、PD的百分比分别为1.8%、27.3%、25.5%和45.5%,RR为29.09%,DCR为54.6%。对照组患者生活质量改善率、稳定率及下降率分别为21.8%、30.9%及47.3%,观察组患者分别为52.7%、23.6%和23.6%。两组患者白细胞减少、血小板减少、恶心呕吐、肝肾功能损害、外周神经损害、心脏毒性、心电图改变比较,差异有统计学意义(P<0.05)。结论重组人血管内皮抑素联合放疗治疗非小细胞肺癌临床效果显著。
Objective To investigate the clinical effect of recombinant human endostatin combined with radiotherapy in the treatment of non-small cell lung cancer. Methods The data of 110 patients with non-small cell lung cancer from February 2010 to February 2013 were retrospectively analyzed. The patients were divided into observation group and control group (55 cases in each group). Patients in the control group were treated with radiotherapy, and patients in the observation group were treated with recombinant human endostatin. The clinical effects of the two groups were compared. Results The percentages of CR, PR, SD and PD in the observation group were 3.6%, 47.3%, 14.5% and 34.6% respectively. The objective effective rate (RR) was 50.9% and the disease control rate (DCR) was 65.5%. The percentages of CR, PR, SD, and PD in the control group were 1.8%, 27.3%, 25.5% and 45.5% respectively. The RR was 29.09% and the DCR was 54.6%. The improvement rate, stability rate and decline rate of the quality of life in the control group were 21.8%, 30.9% and 47.3% respectively, and the observation group were 52.7%, 23.6% and 23.6% respectively. The two groups of patients with leukopenia, thrombocytopenia, nausea and vomiting, liver and kidney dysfunction, peripheral nerve damage, cardiac toxicity, ECG changes, the difference was statistically significant (P <0.05). Conclusion Recombinant human endostatin combined with radiotherapy for the treatment of non-small cell lung cancer has a significant clinical effect.